Biogen Inc

NASDAQ: BIIB
$188.59
+$2.83 (+1.5%)
Closing Price on October 10, 2024

BIIB Stock Chart and Intraday Price

BIIB Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 225 BINNEY STREET, CAMBRIDGE, MA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 32,117.51M USD
Shares Outstanding 145,361,000
Biogen Inc. is a pioneer in the biotechnology sector, focusing on developing treatments for neurological and neurodegenerative conditions. With a global presence, Biogen offers a range of therapies for diseases such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's. Its portfolio includes well-known drugs like TECFIDERA, SPINRAZA, and ADUHELM. Additionally, Biogen is involved in creating biosimilars, which are essentially generic versions of biologic drugs, expanding its impact on healthcare. Founded in 1978 and based in Cambridge, Massachusetts, Biogen continues to push the boundaries of medicine through innovation and partnerships.

BIIB Articles

Dementia is a major healthcare problem across the globe. It is estimated by medical professionals that someone develops some form of dementia every three seconds, and about 55-60 million people...
Friday's top analyst upgrades and downgrades included Apple, Bilibili, Boeing, Carvana, Coty, Estee Lauder, Meta Platforms, Omega Healthcare Investors, RTX, Southwest Airlines and SunPower.
Thursday's top analyst upgrades and downgrades included Alphabet, Eli Lilly, Etsy, Microsoft, Mosaic, NetApp, Omega Healthcare Investors, RTX, Sherwin-Williams, Spotify Technology, Walt Disney and WW...
Tuesday's top analyst upgrades and downgrades included American Express, Apple, AppLovin, Conagra Brands, D.R. Horton, Estee Lauder, Juniper Networks, Livent, Microsoft, Netflix, Nvidia, Shopify,...
Monday's top upgrades and downgrades include Newmont, Paramount Global, JPMorgan Chase, IBM, and Humana.
Tuesday's top analyst upgrades and downgrades included Advance Auto Parts, Alphabet, Biogen, Cheesecake Factory, Chesapeake Energy, Micron Technology, MongoDB, Ross Stores, Tesla and TG Therapeutics.
Wednesday's top analyst upgrades and downgrades included Allstate, Archer Daniels Midland, Avis Budget, Baidu, Centene, Lemonade, Melco Resorts & Entertainment, Palantir Technologies, Peabody Energy,...
Wednesday's top analyst upgrades and downgrades included Chevron, Cleveland-Cliffs, Infosys, Knight-Swift Transportation, Microsoft, Nucor, Salesforce, Steel Dynamics, Wheaton Precious Metals and...
Tuesday's top analyst upgrades and downgrades included Apple, Baidu, Biogen, Comcast, Danaher, Estee Lauder, Exxon Mobil, General Motors, Otis Worldwide, Principal Financial and Zillow.
Friday's top analyst upgrades and downgrades included Affirm, Bank of America, Biogen, Bunge, Coupang, DraftKings, Kosmos Energy, Mattel, Nucor, Nvidia, SentinelOne, SunPower, Vale and Walt Disney.
Thursday's top analyst upgrades and downgrades included AppLovin, Carvana, CrowdStrike, DocuSign, Fisker, Foot Locker, Intuitive Surgical, Rivian Automotive, Shopify, UnitedHealth, Workday and XPO...
Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, Arista Networks, Biogen, CyberArk Software, Global Payments, Kanzhun, Medical Properties Trust, Meta Platforms, Nvidia...
Friday's top analyst upgrades and downgrades included AGNC Investment, Biogen, Cano Health, Carnival, Lithium Americas, Meta Platforms, Seagate Technology, Vertiv, VFC and Waste Management.
Thursday's top analyst upgrades and downgrades included Abbott Laboratories, Biohaven, Edwards Lifesciences, Enphase Energy, Halliburton, Invesco, Liberty Energy, Mattel, Netflix, Permian Resources,...
Wednesday’s additional top analyst upgrades and downgrades were on Ally Financial, Baker Hughes, Biohaven, Biogen, Bumble, Canopy Growth, Corning, Discover Financial Services, Match, Roku and more.